Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Jeffrey Poulton Sells 2,780 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,780 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $366.86 on Thursday. The business has a 50 day moving average of $422.03 and a 200-day moving average of $421.56. The company has a market capitalization of $48.47 billion, a P/E ratio of 1,528.58 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. OFI Invest Asset Management lifted its stake in Alnylam Pharmaceuticals by 5.8% in the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 22 shares during the period. Howard Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.9% during the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 24 shares during the period. Frank Rimerman Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 2.0% during the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 25 shares during the period. Finally, Meridian Financial Advisors LLC increased its stake in Alnylam Pharmaceuticals by 3.5% in the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the topic of several analyst reports. Leerink Partners reduced their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Oppenheimer began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target for the company. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Finally, Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $490.96.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham published a bullish forecast expecting strong price appreciation for ALNY, citing upside from the company’s longer-term growth plan. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: A Yahoo Finance piece examined Alnylam’s valuation in light of the newly unveiled Alnylam 2030 plan — useful context for investors weighing the company’s premium valuation against projected revenue/profitability milestones. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: CEO Yvonne Greenstreet discussed development priorities and the path to profitability in a media interview — helpful for understanding management’s messaging but not new data. Alnylam Pharmaceuticals CEO on development goals, profitability
• Negative Sentiment: Bank of America issued a pessimistic forecast for ALNY, adding downward analyst pressure after the guidance/2030 announcement. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
• Negative Sentiment: Market reaction: a Yahoo report noted ALNY slid sharply after the ambitious 2026 guidance and 2030 plan reveal — indicates investor concern about near-term targets or execution risk. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Multiple insiders (including CEO Yvonne Greenstreet and several EVPs) disclosed sizable stock sales on Jan. 12–13, reducing ownership by ~4–11% in individual cases — typically viewed as a negative signal or a source of additional selling pressure. SEC filing example: SEC filing — Yvonne Greenstreet sale

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.